Chieti

• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511360-87-00 5 2024-10-02 hidradenitis suppurativa (HS)
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 5 2024-04-09 Choroidal neovascularization secondary to pathologic myopia
• RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC … Ended
  2023-504759-28-00 5 2024-04-05 Ocular Hypertension
• A study to learn how well the study treatment finerenone works and how safe it is in people with long-term decrease in the kidneys’ ability … Ended
  2022-503024-27-00 5 2024-02-27 Chronic kidney disease associated with type 1 diabetes mellitus
• Open-label study to evaluate metreleptin in children under 6 years of age with generalised lipodystrophy Ended
  2022-501781-22-00 5 2024-02-09 Generalised lipodystrophy
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight … Ended
  2022-502678-18-00 5 2023-11-07 Type 2 diabetes
• Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy Ended
  2022-502080-38-00 5 2023-10-16 Moderate to severe rotator cuff tendinopathy
• A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase … Ended
  2022-502833-25-00 5 2023-08-02 Obesity
• This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended
  2023-504869-23-00 11 2023-05-31 Dermatitis atopic
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended
  2022-501540-15-00 5 2023-04-25 Atopic Dermatitis
• An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended
  2024-515185-13-00 5 2022-12-21 geographic atrophy
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: … Ended
  2024-517183-31-00 4 2022-11-18 High Risk Rectal Cancer
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 10 2022-09-13 venous thromboembolism (VTE) in patients with gastrointestinal/genitou
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Ended
  2024-514570-43-00 5 2022-01-24 Renal cell carcinoma
• A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended
  2024-512879-13-00 5 2021-09-23 Neovascular age-related macular degeneration (wet AMD)
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 6 2019-07-25 Rheumatoid Arthritis
• Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended
  2024-514515-10-00 5 2016-06-16 Breast Cancer

Showing 49–70 of 70 trials